Injective combine une L1 finance performante et une conception de burn INJ 3.0 solide, mais la TVL et les frais restent trop faibles.
Investment View
Injective avance avec performance et recit deflationniste, mais liquidite financiere et financement du burn restent a verifier.
Source PDF
The PDF report is available alongside the slide viewer.
Report Type
Project Maturity Analysis
Version
v1
Analysis Date
9 juin 2026
Language
fr
Disclaimer: This report is generated through AI-powered analysis and market data. This is not investment advice. All investment decisions should be made at your own risk.